Most recently, Mr. Karl advised on several sell-side pharma transactions for private equity firms and corporates, including a U.S. manufacturer of respiratory and ophthalmic drugs that was sold to a European-Asian private equity fund and a manufacturer of generic liquid pharmaceuticals sold to a partnership formed by a private equity fund. Mr. Karl also performed two reverse due diligence engagements for public biopharmaceutical companies that successfully defended against unsolicited takeover offers.

Mr. Karl broadened his private equity experience with the Private Equity and Principal Investments Group for the Lehman Brothers estate, which was restructured under Chapter 11. His primary responsibilities included portfolio management for venture capital investments, monitoring performance, evaluating and executing transactions, restructuring distressed investments, and recommending investment alternatives based on risk analysis.

Prior to joining A&M, Mr. Karl was a Manager with the PricewaterhouseCoopers LLP assurance and business advisory services practice, where he was an instrumental member of the pharmaceutical industry practice. He performed various consulting roles with Fortune 100 companies and served in PwC’s sports industry practice, leading multiple engagements for the NBA and NFL.

Previously, Mr. Karl worked in the assurance and advisory services group of Arthur Andersen LLP in New York. Among his most notable achievements there was the preparation of a Form S-1 in conjunction with Medco Health Solutions’ initial public offering, a spin-off from Merck valued at over $10 billion.

Mr. Karl earned a bachelor’s degree in accounting from Fairfield University, where he was a member of the Alpha Sigma Nu Honor Society. He is a licensed Certified Public Accountant in New York and New Jersey, and a member of the American Institute of Certified Public Accountants (AICPA).